
The network of laboratories "Invitro" suspends testing for quantitative antibodies to coronavirus due to a shortage of reagents. This was reported to RBC in the press service of the company.
In Vitro explained that due to the explosive demand for tests, they were forced to transfer all laboratory complexes to round-the-clock work, they are now purchasing new equipment and introducing additional shifts in laboratories.
“We are indeed experiencing a shortage of reagents, so we are very sorry to announce that we are pausing sales of the quantitative antibody test for seven to 10 days,” the company said.
US experience: why you should not do an antibody test before and after vaccination Society
Now the network of laboratories is waiting for the supply of reagents, after which it intends to resume research in full. During the suspension period, Invitro will offer citizens a new quantitative antibody test based on a different test system. It will be available in limited quantities in the busiest regions: Moscow, St. Petersburg , Novosibirsk, the Urals.
video
“Previously, we tested on the Abbott test system, we are waiting for delivery from them. Now we are temporarily doing it on the Vector-best system, - they added to Invitro.
Increased demand for testing for coronavirus antibodies arose amid reports of the spread of the "delta" variant (the so-called Indian strain).
The operational headquarters refused to consider antibodies a contraindication for vaccination Society
The capital’s operational headquarters for combating COVID-19 emphasized that the presence of antibodies is not a contraindication for vaccination. The authorities explained that antibody titers do not equate to vaccination, and there is no single method for measuring antibodies.
According to Denis Protsenko, head physician of the hospital in Kommunarka, about 8-10% of vaccinated citizens may not develop antibodies. The production of antibodies in 90% of the vaccinated physician called a good indicator.
Video for this news